tert-butyl 4-(6-chloro-N-methylpyridazine-3-carboxamido)piperidine-1-carboxylate

Catalog No.: 
ACBOOH033
CAS No.: 
2377031-31-5
Molecular Formula: 
C16H23ClN4O3
Molecular Weight: 
354.84
tert-butyl 4-(6-chloro-N-methylpyridazine-3-carboxamido)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-butyl 4-(6-chloro-N-methylpyridazine-3-carboxamido)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(6-chloro-N-methylpyridazine-3-carboxamido)piperidine-1-carboxylate
Molecular FormulaC16H23ClN4O3
Molecular Weight354.84
SMILESCN(C(=O)C1=CC=C(Cl)N=N1)C1CCN(C(=O)OC(C)(C)C)CC1
InChI KeyOSBHATZXJZKLDK-UHFFFAOYSA-N
Synonym1-Piperidinecarboxylic acid, 4-[[(6-chloro-3-pyridazinyl)carbonyl]methylamino]-, 1,1-dimethylethyl ester
CAS No.2377031-31-5

Synthetic Route by SureRoute

1. ACBOOH033 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHDRZ650 route compound structure diagram
    ACHDRZ650147539-41-1In Stock
  2. Plus
  3. ACBPVL437 route compound structure diagram
    ACBPVL4375096-73-1In Stock
  4. Then
  5. ACBOOH033 route product structure diagram
    ACBOOH0332377031-31-5
Inquiry

2. ACBOOH033 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHQWJ290 route compound structure diagram
    ACHQWJ29075680-92-1In Stock
  2. Plus
  3. ACHDRZ650 route compound structure diagram
    ACHDRZ650147539-41-1In Stock
  4. Then
  5. ACBOOH033 route product structure diagram
    ACBOOH0332377031-31-5
Inquiry

3. ACBOOH033 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBOOH033 route product structure diagram
    ACBOOH0332377031-31-5
Inquiry

Comments (0)